| Literature DB >> 28899907 |
Qihong Zhao1, Taeg Kim2, Jian Pang2, Wendy Sun2, Xiaoxia Yang2, Jinhong Wang2, Yunling Song3, Hongwei Zhang3, Huadong Sun3, Vangipuram Rangan4, Shrikant Deshpande4, Huaping Tang3, Mary Ellen Cvijic3, Richard Westhouse3, Timothy Olah3, Jenny Xie2, Mary Struthers2, Luisa Salter-Cid2.
Abstract
IFN-γ-inducible protein 10 (CXCL10), a chemokine that is abundantly secreted in response to inflammatory stimuli, has been implicated in the pathogenesis of multiple inflammatory diseases, such as inflammatory bowel disease. Whereas CXCL10 is traditionally recognized for recruiting pathogenic T cells to inflamed sites, its nonchemotactic role during inflammation remains poorly defined. In this report, we identified a novel function of CXCL10 in the regulation of the inflammatory potential of human monocytes to produce cytokines. We found that CXCL10 was necessary and sufficient for IFN-γ-primed human monocytes to induce a robust production of proinflammatory cytokines, such as IL-12 and IL-23. CXCL10-induced monocyte production of these cytokines depended on CXCR3 receptor engagement as well as on the Iκ B kinase and p38 MAPK signaling pathways. By using an innate-mediated murine colitis model, we demonstrated that anti-CXCL10 Ab treatment robustly suppressed the local production of myeloid-derived inflammatory cytokines and intestinal tissue damage. Together, our data unravel a previously unappreciated role of CXCL10 in the amplification of myeloid cell-mediated inflammatory responses. Targeting CXCL10 is therefore an attractive approach to treating inflammatory diseases that are driven by innate and adaptive immunity. © Society for Leukocyte Biology.Entities:
Keywords: CXCL10; CXCR3; IFN-γ; IL-12; inflammatory bowel disease; monocyte
Mesh:
Substances:
Year: 2017 PMID: 28899907 DOI: 10.1189/jlb.5A0717-302
Source DB: PubMed Journal: J Leukoc Biol ISSN: 0741-5400 Impact factor: 4.962